Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Afferent Pharmaceuticals, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
This study is a double-blind, placebo-controlled, randomized trial designed to assess the efficacy and safety of gefapixant in female participants with moderate to severe pain associated with IC/BPS. The study will consist of 4 phases: Screening, Baseline, Treatment, and Follow-up.
Age
18–80
Sex
FEMALE
Healthy volunteers
Not accepted
You may be eligible if
Women
Women of child bearing potential must not be pregnant during the study and must use two forms of birth control
Clinical evidence of Interstitial Cystitis /Bladder Pain Syndrome (IC/BPS)
Have provided written informed consent
You may not be if
History of diseases that can be confused for IC/BPS
Unable to void spontaneously
Immunosuppressant, intravesicular, nerve stimulator or opioid treatment for certain periods prior to start of the study
Changes to doses of Elmiron®, antidepressant, alpha-adrenergic antagonist, H1 antagonist, or anti-muscarinic treatment within a certain period prior to the start of the study
Clareo Health | The Safety and Efficacy of Gefapixant (AF-219/MK-7264) in Female Participants With Interstitial Cystitis /Bladder Pain Syndrome (MK-7264-005)
